Radiation Therapy Oncology Group 0521: A phase III randomized trial of androgen suppression and radiation therapy versus androgen suppression and radiation therapy followed by chemotherapy with docetaxel/prednisone for localized, high-risk prostate cancer

Clinical Genitourinary Cancer

Volumn 4, Issue 3, 2005, Pages 212-214

  Patel, Asmita R ^a   Sandler, Howard M ^b   Pienta, Kenneth J ^b,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Hormone naive disease; Intensity modulated radiation therapy; Locally advanced disease

Indexed keywords

ANTIANDROGEN; DOCETAXEL; GONADORELIN AGONIST; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; CORTICOSTEROID; TAXOID;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; GLEASON SCORE; HUMAN; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; PROSTATE CANCER; SHORT SURVEY; TREATMENT PLANNING; ARTICLE; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; MALE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROSTATE TUMOR; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; COMBINED MODALITY THERAPY; HUMANS; MALE; NEOPLASM STAGING; PREDNISONE; PROSTATIC NEOPLASMS; RADIOTHERAPY; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 33644961408     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2005.n.035     Document Type: Article

References (10)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005 [published erratum in CA Cancer J Clin 2005; 55:259]. CA Cancer J Clin 2005; 55:1-30.
2. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512.
3. Pilepich MV, Winter K, John, MJ, et al. Phase III RTOG trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50:1243-1252.
4. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-13. Int J Radiat Oncol Biol Phys 2005; 61:1285-1290.
5. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 2002; 360:103-106.
6. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of prostate: the RTOG protocol 92-02. J Clin Oncol 2003; 21:3972-3978.
7. Roach M 3rd, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: RTOG 9413. J Clin Oncol 2003; 21:1904-1911.
8. Sandler H, DeSilvio M, Pienta K, et al. Preliminary analysis of RTOG 9902: increased toxicity observed with the use of adjuvant chemotherapy: Proc Amer Soc Thera Rad Onc 2005; 63(suppl 1):123 (Abstract #203).
9. Pisansky TM, Kahn MJ, Bostwick DG. An enhanced prognostic system for clinically localized carcinoma of the prostate. Cancer 1997; 79:2154-2161.
10. Zelen M. The randomization and stratification of patients to clinical trials. J Chron Dis 1974; 27:365-375.